Trastuzumab, the firstly generated monoclonal antibody (mAB) that targets HER2 and which could enhance the overall survival of HER2 patients overexpressing advanced GC/GEJC (Aoki et al., 2021]. Here, ERBB2 is linked to gastric cancer.